1596. Ceftolozane/tazobactam (Zerbaxa) for the Treatment of Pseudomonas aeruginosa (PSA) Bacteremia: A Systematic Literature Review (SLR)

菌血症 医学 重症监护医学 他唑巴坦 内科学 肺炎 铜绿假单胞菌 医院获得性肺炎 梅德林 人口 头孢菌素 经验性治疗 抗生素 抗生素耐药性 微生物学 法学 遗传学 环境卫生 政治学 亚胺培南 生物 细菌
作者
Ryan James Dillon,Z. Khankhel,Carisa S. De Anda,Christopher J. Bruno,Laura Puzniak
出处
期刊:Open Forum Infectious Diseases [Oxford University Press]
卷期号:7 (Supplement_1): S794-S794 被引量:2
标识
DOI:10.1093/ofid/ofaa439.1776
摘要

Background Bacteremia is a significant cause of morbidity and mortality. Several studies have shown this burden to increase among patients with multidrug resistant (MDR) PSA, and in those treated with inappropriate empiric therapy. Ceftolozane/tazobactam (C/T) is a combination of a novel antipseudomonal cephalosporin and an established β-lactamase inhibitor approved for the treatment of complicated urinary tract infection, complicated intra-abdominal infection and hospital-acquired and ventilator-associated bacterial pneumonia. In the absence of specific bacteremia clinical trial data; the aim of this study is to describe all published evidence relating to C/T for the treatment of Gram negative bacteremia. Methods This SLR includes all published evidence from December 2015 to March 2020 searched via the OVID platform: EMBASE, MEDLINE, and MEDLINE In-Process. In addition, data published (2018-2019) from the European Society of Clinical Microbiology and Infectious Diseases and Infectious Disease Week Congresses were included. Eligible publications were on adult patients treated with C/T reporting any clinical outcome where data were reported specifically for the bacteremia population. Results The SLR identified 1,455 citations, of which 24 publications representing 23 unique studies met eligibility criteria. This included primary and secondary bacteremia. Ten studies included patients with primary bacteremia, only 7 of which reported results specific to primary bacteremia patients. Despite heterogeneity in study design, patient and treatment characteristics, and a lack of detailed reporting; the majority of studies focused on MDR/ extensively drug resistant (XDR) infections (range: 68.3%-100%). Clinical success/ cure ranged from 33%-100%, with 6/7 studies at >85%; 30-day mortality from 0%-67%, with 3/7 studies at 0% (Table 1). Table 1. Clinical Outcomes reported among Primary Bacteremia population(s) Conclusion Although the number of C/T treated patients was small, favorable clinical outcomes were observed, even among highly resistant PSA infections. Heterogeneity was ubiquitous, with diverse and complex patient profiles identified. Further studies where outcomes are stratified by bacteremia status and by timing of C/T treatment are needed. Disclosures Ryan J. Dillon, MSc, Merck & Co., Inc., (Employee) Carisa De Anda, PharMD, Merck & Co Inc, (Employee) Christopher Bruno, MD, Merck & Co., Inc. (Employee) Laura A. Puzniak, PhD, Merck (Employee)

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
充电宝的应助被Rina采纳,获得10
1秒前
No4关闭了No4的文献求助
2秒前
2秒前
smile完成签到,获得积分10
2秒前
2秒前
lin完成签到,获得积分10
3秒前
王文鑫完成签到 ,获得积分10
4秒前
Seorina发布了新的文献求助10
4秒前
科研通AI6.3的应助被yyyyyy采纳,获得10
6秒前
6秒前
7秒前
DYY发布了新的文献求助10
7秒前
Maestro_S的应助被yuan采纳,获得10
8秒前
8秒前
谦让白亦完成签到,获得积分20
9秒前
Lucas的应助被远了个方采纳,获得10
9秒前
Hello的应助被远了个方采纳,获得10
9秒前
小二郎的应助被远了个方采纳,获得10
9秒前
Jasper的应助被远了个方采纳,获得10
9秒前
10秒前
10秒前
11秒前
明杰完成签到,获得积分10
11秒前
11秒前
诚心求文发布了新的文献求助10
13秒前
牢牛马发布了新的文献求助10
14秒前
15秒前
16秒前
17秒前
dd36完成签到,获得积分10
18秒前
小饭发布了新的文献求助10
18秒前
flyzky发布了新的文献求助10
18秒前
18秒前
19秒前
20秒前
Orange的应助被Nicolesix采纳,获得10
21秒前
yjsshr发布了新的文献求助10
21秒前
潍潍完成签到 ,获得积分10
21秒前
云泪天痕的应助被ccccelia采纳,获得10
22秒前
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192903
求助须知:如何正确求助?哪些是违规求助? 9579346
关于积分的说明 21864636
捐赠科研通 7792529
什么是DOI,文献DOI怎么找? 3437107
关于科研通互助平台的介绍 2560653
邀请新用户注册赠送积分活动 2483937